Standing by people with sickle cell disease and their families

As a company, we stand up for greater inclusion of LGBTI people because when each of us feels included, we all benefit.

Novartis condemns the war in Ukraine and has been providing humanitarian support, financial donations as well as considerable volumes of medicines to those people impacted by the war.

Novartis is committed to reimagining the fight against Chagas Disease and advocating for an integrated, end-to-end care approach.

Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.

Latest oncology resources and news surrounding Novartis data featured at European Society for Medical Oncology (ESMO)

AI offers the greatest potential to transform health systems from being reactive to proactive, predictive, and even preventive.

European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

COVID-19 is disrupting Africa’s health services – potentially undermining decades of progress on child health.